Wlodzimierz Mazur

Medical University of Silesia

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (13)

Rafal Krygier

head

POLAND

View details

Dorota Zarębska-Michaluk

Jan Kochanowski University

POLAND

View details

Robert Flisiak

Medical University of Białystok

POLAND

View details

Krystyna Dobrowolska

Jan Kochanowski University

POLAND

View details

Diana Martonik

Medical University of Białystok

POLAND

View details

Ewa Janczewska

Medical University of Silesia

POLAND

View details

Regina Podlasin

Cardinal Stefan Wyszyński University in Warsaw

POLAND

View details

Brygida Adamek

Medical University of Silesia

POLAND

View details

Barbara Sobala-Szczygiel

Medical University of Silesia

POLAND

View details

Krzysztof Simon

MD,PhD.Prof; Head of the Department

Medical University of Silesia

POLAND

View details

Anna Piekarska

Proff

Medical University of Lodz

POLAND

View details

Anna Szymanek-Pasternak

Wroclaw Medical University

POLAND

View details

Jerzy Jaroszewicz

Medical University of Silesia

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Wlodzimierz Mazur

Research Interests

Explore related searches

Contact this professor

Articles (20)

Sustained Virological Response After Early Discontinuation of Hepatitis C Treatment

Direct‐acting antivirals in women of reproductive age infected with hepatitis C virus

Treatment of Hepatitis C Virus Infections Among Patients of Ukrainian Origin During the Influx of War Refugees to Poland

Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices.

Treatment of the most difficult-to-cure hepatitis C virus-infected population with sofosbuvir / velpatasvir.

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland

Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?

Pangenotypic triple <i>versus</i> double therapy in HCV-infected patients after prior failure of direct-acting antivirals.

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders.

Impact of Kidney Failure on the Severity of COVID-19

Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.

Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study.

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?

Changes of patient profile, treatment effectiveness and safety during 4 years access to interferon-free therapy for hepatitis C virus infection.

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naive patients infected with HCV genotype 1b with non-advanced hepatic fibrosis.

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.

Real life results of direct acting antiviral therapy for HCV infection in HIVHCVcoinfected patients: Epi-Ter2 study.

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with HCV genotype 1 and 4.

Collaborators (13)

Rafal Krygier

Dorota Zarębska-Michaluk

Robert Flisiak

Krystyna Dobrowolska

Diana Martonik

Ewa Janczewska

Regina Podlasin

Brygida Adamek

Barbara Sobala-Szczygiel

Krzysztof Simon

Anna Piekarska

Anna Szymanek-Pasternak

Jerzy Jaroszewicz

Make your next move.

Wlodzimierz Mazur

Research Interests

Explore related searches

Contact this professor

Articles (20)

Sustained Virological Response After Early Discontinuation of Hepatitis C Treatment

Direct‐acting antivirals in women of reproductive age infected with hepatitis C virus

Treatment of Hepatitis C Virus Infections Among Patients of Ukrainian Origin During the Influx of War Refugees to Poland

Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices.

Treatment of the most difficult-to-cure hepatitis C virus-infected population with sofosbuvir / velpatasvir.

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland

Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?

Pangenotypic triple <i>versus</i> double therapy in HCV-infected patients after prior failure of direct-acting antivirals.

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders.

Impact of Kidney Failure on the Severity of COVID-19

Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.

Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study.

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?

Changes of patient profile, treatment effectiveness and safety during 4 years access to interferon-free therapy for hepatitis C virus infection.

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naive patients infected with HCV genotype 1b with non-advanced hepatic fibrosis.

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.

Real life results of direct acting antiviral therapy for HCV infection in HIVHCVcoinfected patients: Epi-Ter2 study.

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously &quot;difficult to treat&quot; patients infected with HCV genotype 1 and 4.

Collaborators (13)

Rafal Krygier

Dorota Zarębska-Michaluk

Robert Flisiak

Krystyna Dobrowolska

Diana Martonik

Ewa Janczewska

Regina Podlasin

Brygida Adamek

Barbara Sobala-Szczygiel

Krzysztof Simon

Anna Piekarska

Anna Szymanek-Pasternak

Jerzy Jaroszewicz

Make your next move.

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with HCV genotype 1 and 4.